RecruitingPhase 3NCT06004856
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
- Intervention
- Orelabrutinib(drug)
- Enrollment
- 195 enrolled
- Eligibility
- 18-80 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
- The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
- Beijing CHAO-YANG Hospital Capital Medcal University, Beijing, Beijing Municipality, China
- Peking university People's Hospital, Beijing, Beijing Municipality, China
- Xinqiao Hospital of Army Medical University, Chongqing, Chongqing Municipality, China
- Fujian Medical University Union Hospital, Fuzhou, Fujian, China
- The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
- Zhongshan Hospital Xiamen University, Xiamen, Fujian, China
- Gansu Provincial Hospital, Lanzhou, Gansu, China
- Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
- Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, Guangdong, China
- The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
- North China University of Science and Technology Affiliated Hospital, Tangshan, Hebei, China
- The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China
- The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06004856 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation